1-11 of 11
Amy S. Kimball
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I/II Clinical Trial of Temsirolimus and Lenalidomide in Patients with Relapsed and Refractory Lymphomas

Ajay Major, MDMBA, Justin Kline, MD, Theodore G. Karrison, PhD, Paul A S Fishkin, MD, Amy S Kimball, MD PhD, Adam M Petrich, MD, Sreenivasa Nattam, MD, Bethany G Sleckman, MD, Kenneth Cohen, MD, Koen van Besien, MD PhD, Aaron P. Rapoport, MD, Sonali M. Smith, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 43–44.
https://doi.org/10.1182/blood-2020-134750
Published: 2020
Journal Articles

Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR

Clinical Trials & Observations
Meletios Dimopoulos, David Siegel, Darrell J. White, Ralph Boccia, Karim S. Iskander, Zhao Yang, Amy S. Kimball, Khalid Mezzi, Heinz Ludwig, Ruben Niesvizky
Journal: Blood
Blood (2019) 133 (2): 147–155.
https://doi.org/10.1182/blood-2018-06-860015
Published: 2019
Includes: Supplemental data
Journal Articles

Efficacy and Safety of Carfilzomib and Dexamethasone in Lenalidomide Exposed and Refractory Multiple Myeloma Patients: Combined Analysis of Carfilzomib Trials

Maria-Victoria Mateos, MD PhD, Jesus G. Berdeja, MD, Meletios A Dimopoulos, MD, David S Siegel, MD PhD, P Joy Ho, MBBS(Syd) DPhil(Oxon) FRACP FRCPA FFSc(RCPA), Mei Huang, Martina Sersch, Anita Zahlten-Kumeli, Amy S Kimball, Katja Weisel, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1963.
https://doi.org/10.1182/blood-2018-99-112600
Published: 2018
Journal Articles

Overall Survival of Relapsed/Refractory Multiple Myeloma Patients Treated with Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone: Results from the Phase 3 Endeavor Study According to Age Subgroup

Ruben Niesvizky, MD, Heinz Ludwig, MD, Andrew Spencer, MD, Hartmut Goldschmidt, MD, Tomas Pika, Maria-Victoria Mateos, Meletios A. Dimopoulos, Lifen Zhou, Amy S. Kimball, Thierry Facon, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1885.
https://doi.org/10.1182/blood.V130.Suppl_1.1885.1885
Published: 2017
Journal Articles

Comparison of Proteasome Inhibition Activity between Carfilzomib and Bortezomib in the Phase 3 Endeavor Study

Heinz Ludwig, MD, Andrew Spencer, MD, Tibor Kovacsovics, Nashat Y. Gabrail, Leonard Minuk, Amy S. Kimball, Robert J. Pelham, Ying C. Ou, Robert Z. Orlowski, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3125.
https://doi.org/10.1182/blood.V130.Suppl_1.3125.3125
Published: 2017
Journal Articles

Superior Efficacy of Carfilzomib and Dexamethasone (Kd56) Vs Bortezomib and Dexamethasone (Vd) in Multiple Myeloma (MM) Patients with Moderate or Serious Renal Failure: A Subgroup Analysis of the Phase 3 Endeavor Study

Meletios A. Dimopoulos, David Siegel, MD PhD, Darrell J. White, MD, Ralph V. Boccia, Zhao Yang, Amy S. Kimball, Karim Saad Iskander, Khalid Mezzi, MD MBA, Heinz Ludwig, MD, Ruben Niesvizky, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1845.
https://doi.org/10.1182/blood.V130.Suppl_1.1845.1845
Published: 2017
Journal Articles

Genomic Predictors of Progression-Free Survival Among Patients with Relapsed or Refractory Multiple Myeloma Treated with Carfilzomib and Dexamethasone or Bortezomib and Dexamethasone in the Phase 3 Endeavor Trial

Robert J Pelham, PhD, Xuguang Hu, PhD, Philippe Moreau, MDPhD, Albert Oriol, MD, Hang Quach, MBBS (Hons), FRACP, FRCPA, MD, Tibor Kovacsovics, Jonathan J Keats, PhD, Shibao Feng, PhD, Amy S. Kimball, Meletios A. Dimopoulos
Journal: Blood
Blood (2017) 130 (Supplement 1): 839.
https://doi.org/10.1182/blood.V130.Suppl_1.839.839
Published: 2017
Journal Articles

Overall Survival of Patients with Relapsed Multiple Myeloma Treated with Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone According to Prior Line of Therapy and Previous Exposure to Bortezomib: Secondary Analysis of the Phase 3 Endeavor Study

Katja C. Weisel, David Siegel, MD PhD, Jesus F. San Miguel, MD, Roman Hájek, MD, P. Joy Ho, MBBS, DPhil, FRACP, FRCPA, FFSc(RCPA), Gianluca Gaidano, MD PhD, Robert Z. Orlowski, MD PhD, Lifen Zhou, Amy S. Kimball, Philippe Moreau, MDPhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1850.
https://doi.org/10.1182/blood.V130.Suppl_1.1850.1850
Published: 2017
Journal Articles

A Phase 1b Study Investigating Carfilzomib Administered Once Weekly in Combination with Lenalidomide and Dexamethasone in Patients with Multiple Myeloma

Noa Biran, David S. Siegel, MD PhD, Jesus G. Berdeja, MD, Edward Faber, Lasika Seneviratne, Melissa Alsina, William Bensinger, Amy S. Kimball, Kefei Zhou, Ola Landgren, MD PhD
Journal: Blood
Blood (2016) 128 (22): 3322.
https://doi.org/10.1182/blood.V128.22.3322.3322
Published: 2016
Journal Articles

A Multicenter, Open-Label, Phase 1b Study of Carfilzomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients (CHAMPION-2)

Ralph V. Boccia, Alberto Bessudo, Richy Agajanian, Paul Conkling, Wael Harb, Hui Yang, Dawn Pinchasik, Amy S. Kimball, James R. Berenson, MD
Journal: Blood
Blood (2016) 128 (22): 3325.
https://doi.org/10.1182/blood.V128.22.3325.3325
Published: 2016
Journal Articles

Multicenter Phase 1b Dose-Escalation Study of Ibrutinib and Lenalidomide Combined with Dose-Adjusted EPOCH-R in Patients with Relapsed/Refractory DLBCL

Wyndham H. Wilson, MD PhD, Leslie L. Popplewell, MD, Tycel Phillips, MD, Amy S. Kimball, MD PhD, Saurabh Chhabra, MD, Jerry Ping, PhD, Jutta Neuenburg, MD, Nora Cavazos, MD, Louis M Staudt, MD, Sven de Vos, MD PhD
Journal: Blood
Blood (2015) 126 (23): 1527.
https://doi.org/10.1182/blood.V126.23.1527.1527
Published: 2015